S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
NASDAQ:EDSA

Edesa Biotech (EDSA) Stock Price, News & Analysis

$4.34
-0.01 (-0.23%)
(As of 04/17/2024 ET)
Today's Range
$4.34
$4.40
50-Day Range
$4.06
$5.67
52-Week Range
$2.46
$8.61
Volume
568 shs
Average Volume
12,993 shs
Market Capitalization
$13.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.00

Edesa Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
798.6% Upside
$39.00 Price Target
Short Interest
Healthy
0.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$20,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.32) to ($1.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

465th out of 914 stocks

Pharmaceutical Preparations Industry

204th out of 407 stocks

EDSA stock logo

About Edesa Biotech Stock (NASDAQ:EDSA)

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

EDSA Stock Price History

EDSA Stock News Headlines

EDSA: Development of EB05 in ARDS Continues…
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Edesa Biotech Inc (EDSA)
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Edesa Biotech Reports Fiscal Year 2023 Results
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Edesa Biotech Inc EDSA
Edesa Biotech Announces One-for-Seven Reverse Share Split
See More Headlines
Receive EDSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EDSA
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.00
High Stock Price Target
$57.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+786.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.34 per share

Miscellaneous

Free Float
2,412,000
Market Cap
$14.17 million
Optionable
Not Optionable
Beta
0.32
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

EDSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Edesa Biotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EDSA shares.
View EDSA analyst ratings
or view top-rated stocks.

What is Edesa Biotech's stock price target for 2024?

2 Wall Street analysts have issued 12 month target prices for Edesa Biotech's stock. Their EDSA share price targets range from $21.00 to $57.00. On average, they predict the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 798.6% from the stock's current price.
View analysts price targets for EDSA
or view top-rated stocks among Wall Street analysts.

How have EDSA shares performed in 2024?

Edesa Biotech's stock was trading at $4.57 at the beginning of 2024. Since then, EDSA shares have decreased by 5.0% and is now trading at $4.34.
View the best growth stocks for 2024 here
.

Are investors shorting Edesa Biotech?

Edesa Biotech saw a increase in short interest in March. As of March 31st, there was short interest totaling 19,500 shares, an increase of 10.2% from the March 15th total of 17,700 shares. Based on an average daily volume of 13,800 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the shares of the stock are sold short.
View Edesa Biotech's Short Interest
.

When is Edesa Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EDSA earnings forecast
.

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) issued its earnings results on Friday, February, 9th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($1.21) by $0.67.

When did Edesa Biotech's stock split?

Shares of Edesa Biotech reverse split on Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), AT&T (T) and Amarin (AMRN).

How do I buy shares of Edesa Biotech?

Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDSA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners